Business Wire

Crown Bioscience Publishes New Study in PLOS ONE Highlighting the Use of Clinically Relevant 3D In Vitro PDX-Derived Organoid Models as Powerful Tools to Accelerate Cancer Drug Discovery

Share

Crown Bioscience, a global contract research organization (CRO), and JSR Life Sciences company, announced today their newly published study in PLOS ONE, a journal of the Public Library of Science (PLOS), demonstrating the establishment and application of a highly clinically relevant 3D in vitro PDX-derived organoid (PDXO) biobank for higher-throughput screening for cancer drug discovery.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230105005843/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Rajendra Kumari, PhD, Executive Director of Integrated Solutions at Crown Bioscience (Photo: Business Wire)

This study aligns well with the recent Senate Bill 5002, titled FDA Modernization Act 2.0, introduced in the United States Senate, which authorizes the use of alternatives to animal testing, including cell-based assays for the purposes of drug and biological product applications.

“This invaluable publication demonstrates our ongoing commitment to develop innovative preclinical models for our customers by including the provision of robust and clinically relevant in vitro solutions as early as possible in the drug development process followed with matched translational models downstream,” commented Rajendra Kumari, PhD, Executive Director of Integrated Solutions at Crown Bioscience. “Organoids maintain a high degree of clinical relevance that cannot be achieved with traditional 2D cell lines and other 3D systems. As a result, in vitro drug screening with PDXOs represents a highly physiologically relevant platform that better predicts patient response making these ideal alternatives to animal testing.”

This new study reports on the largest living, commercially available PDXO biobank—with approximately 550 tumor organoid models derived from a collection of matched PDXs representing 17 different types of carcinomas. The main findings of the study include:

  • The biological equivalence and interchangeability between PDXOs and parental PDXs were confirmed based on genomics, histopathology, and pharmacology.
  • PDXOs in 384-well format assays are reliable, robust, and suitable for higher-throughput screening for rapid identification of drug sensitivity and drug combination strategies, including for matrix screening, encompassing both lead compounds and indications.
  • PDXOs are amenable to engineering, such as gene editing to significantly broaden large-scale research applications, including in vitro/in vivo imaging analysis.
  • The successful co-culture of PDXOs with PBMCs and CAR-T cells to investigate immune modulation and tumor killing.

This large biobank provides a unique collection of matched in vitro and in vivo preclinical patient-derived models which can be accessed via Crown Bioscience’s online databases OrganoidBase™ and HuBase™. This powerful translational tool has distinct advantages over other systems such as providing higher throughput with faster results as compared to in vivo models alone, with robust and renewable assay performance that reflects reproducibility of other in vitro systems. In vitro drug screening with PDXOs can rapidly be integrated into early drug development and interchangeably with translational studies and improved predictions of clinical outcome.

To read the full publication entitled “A living biobank of matched pairs of patient-derived xenografts and organoids for cancer pharmacology”, follow this link.

###

About Crown Bioscience

Crown Bioscience is a global CRO that provides preclinical and translational platforms to help our customers advance their research and development in oncology, immuno-oncology, and immune-mediated inflammatory diseases (IMID). Crown Bioscience is the exclusive preclinical CRO to offer tumor organoid services, utilizing Hubrecht Organoid Technology (HUB) to establish 3D in vitrotumor organoids that have been shown to faithfully recapitulate the phenotypic and genetic features of their original tumor, and these models are playing an increasingly important role in cancer drug discovery, particularly in identifying anticancer agents with improved translational potential. In addition, Crown Bioscience has developed OrganoidBase™, an extensive searchable biobank consisting of hundreds of PDXO models with information on histopathology, IC50, and genomic and transcriptomic analysis data associated with drug response. Crown Bioscience is focused on helping our customers develop novel therapies to help patients receive the right treatment at the right time. Founded in 2006, Crown Bioscience has ten facilities across the US, Europe, and Asia.

For more information or to get in touch, please visit: www.crownbio.com

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media Inquiries:
Louise Stenson
pr@crownbio.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Planview Continues Acceleration with Record Revenue in FY’2230.1.2023 15:00:00 CET | Press release

Planview, the leading platform for connected work from portfolio planning to delivery, today announced record annual recurring revenue (ARR) for fiscal year 2022, continuing a trend of strong performance. Planview exceeded $380 million in total ARR for 2022, representing 17% growth year-over-year (YoY). “It was another record year for Planview, underpinned by our commitment to build the digital future of connected work through product innovation and customer success,” said Razat Gaurav, Chief Executive Officer, Planview. “The macroeconomic uncertainties and headwinds faced by organizations today make prioritizing product and project initiatives, and thoughtfully allocating constrained resources and capital, more important than ever. Our global customer base relies on our solutions to help them achieve productivity, efficiency, and positive business outcomes from transformation initiatives across the enterprise.” Fiscal Year-End Highlights Planview achieved record levels for the full fi

Owlin Launches End-to-End KYC Solution for Payment Service Providers30.1.2023 13:30:00 CET | Press release

Today, AI platform Owlin announced the launch of Owlin for KYC, offering Payment Service Providers (PSPs) a single solution for onboarding, monitoring, and offboarding merchants. With this new solution, Owlin helps PSPs with some of their most pressing priorities around meeting recent regulatory requirements and dealing with the insecurities that come from current economic developments. Owlin for KYC enables PSPs to screen their merchants against multiple data sources, including Adverse Media, Sanctions, Politically Exposed Persons, and Customer Reviews. This latest offering from Owlin will significantly enhance KYC processes, particularly when PSPs manually screen merchants against different data sources to check for risk within their merchant portfolio. Owlin for KYC supports seamless transition from the onboarding phase to continuous monitoring, with all data associated with the onboarding and monitoring steps being retained and available as an end-to-end audit trail. Sarah Lane, Ch

Samsung Electronics Achieves Life Cycle Assessment Verification on Product Carbon Footprint for Semiconductors30.1.2023 10:37:00 CET | Press release

Samsung Electronics Co., Ltd., a world leader in advanced semiconductor technology, today announced that it has established a Life Cycle Assessment (LCA) on the product carbon footprint of its semiconductor business and achieved verification from DNV, one of the world's leading independent certification bodies. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230130005256/en/ Samsung Electronics Achieves Life Cycle Assessment Verification on Product Carbon Footprint for Semiconductors (Photo: Business Wire) LCA is a methodology for assessing environmental impacts throughout the lifecycle of commercial products, processes, or services, by quantifying the amount of energy, materials and waste discharge. In detail, on its semiconductors’ carbon footprint, Samsung's LCA covers raw material extraction to chip manufacturing, assembling, and testing. Its results are in accordance with ISO 14040, ISO 14044 and ISO 14067 to ensure cred

FourKites & cargonerds Partner to Bring Enhanced Cost & Time Savings to Global Freight Forwarders & Shippers30.1.2023 10:00:00 CET | Press release

Leading real-time supply chain visibility company FourKites today announces a partnership with cargonerds to enhance the digital freight platform with its market-leading supply chain visibility data. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230130005027/en/ FourKites & cargonerds partner to bring enhanced cost and time savings to global freight forwarders and shippers (Graphic: Business Wire) Armed with FourKites’ data and machine learning-driven estimated times of arrival, cargonerds can now ensure that its freight forwarders and their customers can track products across the end-to-end supply chain and know exactly when they’ll arrive at their destination. The integrated solution will track global shipments in real time across road, rail, ocean, air, parcel and last mile across the globe. “FourKites has the largest global network of supply chain data and powerful machine learning on the planet,” says Conrad Franchi, f

DEUTZ AG: DEUTZ enters into cooperation with Daimler Truck to develop and market medium- and heavy-duty engines30.1.2023 09:53:00 CET | Press release

The issuer is solely responsible for the content of this announcement. Today, DEUTZ AG (DEUTZ) and Daimler Truck AG (Daimler Truck) signed agreements giving DEUTZ access to Daimler engines by end of the decade. These include both medium-duty engines (Daimler Truck MDEG series), which are suitable for use in applications such as construction equipment, and heavy-duty engines (Daimler Truck HDEP series), which can be used to power heavy agricultural machinery, for example. As a result, DEUTZ will be able to attract new customer groups, save on development costs, expand its range of modern internal combustion engines, and thereby lay the foundations for further growth in this business. The cooperation between the two companies, which is supported by the stake Daimler Truck takes in DEUTZ, is focused on two areas: 1. DEUTZ will acquire the on-highway IP to Daimler Truck’s medium-duty MDEG engines so that it can further develop them itself, including for use in off-highway applications such